Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

a direct license with Orcrist. BioMS assigned all BioMS owned patents relating to HYC750 and transfered all HYC750 assets to Orcrist. Under the terms of the agreement, BioMS will receive certain milestone payments in addition to a royalty on net sales of products which otherwise would have infringed on patents related to the HYC750 technology.

BioMS also ceased all development activities with respect to BioCyDex. Future development or licensing activities will be the responsibility of BioCyDex.

Financial Results

The consolidated net loss for the year ended December 31, 2008 was $0.5 million or ($0.01) per share compared with a consolidated net loss of $47.2 million or ($0.56) per share for the previous year. The consolidated net income for the three months ended December 31, 2008 was $0.3 million or $0.01 per share compared with a net loss of ($11.7) million or ($0.13) per share for the previous year.

Revenue of $52.6 million was recorded for the year ended December 31, 2008 compared to $Nil for the year ended December 31, 2007. The revenue is the result of the amortization of the upfront payment and development milestone received from the Agreement with Lilly. Investment income earned on funds invested for the year ended December 31, 2008 increased to $2.4 million from $1.6 million for 2007 due to the increase in cash and cash equivalents as a result of the Agreement with Lilly. The increase was partially offset by a general reduction in interest rates experienced in the market. The investment income is earned from the short-term investment of cash reserves in low risk term deposits and bankers acceptance notes.

Total consolidated expenses for the year ended December 31, 2008 were $61.9 million compared with $48.0 million for 2007. Total consolidated expenses for the three months ended December 31, 2008 totaled $16.5 million as compared to $12.1 million in the same quarter the previous year.

Research
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Personalized Medicine - Scientific ... , The aim of personalized medicine ... drug to the right patient and, in some ... a patient according to his/her genotype. This report ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and ... the addition of Jain PharmaBiotech,s new report ... to their offering. , Gene ... vectors, nonviral vectors and cell therapy with genetically ... of drug delivery and various routes of administration ...
(Date:3/3/2015)... PHILADELPHIA , March 3, 2015 ... agencies with tools for implementing competency-based training to comply ... DirectCourse is offering a new crosswalk ... Services (HCBS) implement competency-based training for direct service workers ... Medicare & Medicaid Services (CMS) regulations. CMS ...
(Date:3/3/2015)... 2015  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer ... focus on protecting the microbiome, announced today that Jeffrey ... the 27th Annual ROTH Conference being held on March 8-11, ... in Dana Point, CA. Mr. Riley ... 1:00 p.m. (Pacific Time). A live webcast of ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... II still video system to directly acquire,images from ... Moores ,Stratagene , The Eagle Eye ... direct,imaging of chemiluminescent Western blots. The light-tight cabinet ... capture chemiluminescent signals. Also,the systems charge-coupled device (CCD) ...
... BlueNeurons are ideal for use in transplantation studies ... at High,Levels , , Michael McGrogan * Guadalupe ... California , , Stratagene's hNT BlueNeurons express beta-galactosidase ... of the NT2 teratocarcinoma stably transfected with a,lacZ ...
... PCR system, developed for,highfidelity PCR , , Kirk ... Daniel McMullan,* Barbara McGowan * Holly Hogrefe ,Stratagene Cloning ... the TaqPlus Precision PCR system,* to an expanding line ... a novel mixture of Taq2000 and Pfu DNA polymerases ...
Cached Biology Technology:Imaging Chemiluminescent Western Blots 2Imaging Chemiluminescent Western Blots 3hNT BlueNeurons Express b-Galactosidase at High ,Levels 2hNT BlueNeurons Express b-Galactosidase at High ,Levels 3hNT BlueNeurons Express b-Galactosidase at High ,Levels 4hNT BlueNeurons Express b-Galactosidase at High ,Levels 5High-Fidelity PCR with a Novel Polymerase Mixture 2High-Fidelity PCR with a Novel Polymerase Mixture 3High-Fidelity PCR with a Novel Polymerase Mixture 4High-Fidelity PCR with a Novel Polymerase Mixture 5High-Fidelity PCR with a Novel Polymerase Mixture 6High-Fidelity PCR with a Novel Polymerase Mixture 7High-Fidelity PCR with a Novel Polymerase Mixture 8High-Fidelity PCR with a Novel Polymerase Mixture 9High-Fidelity PCR with a Novel Polymerase Mixture 10High-Fidelity PCR with a Novel Polymerase Mixture 11
(Date:2/25/2015)... , Feb. 25, 2015  ABC Financial ... billing in the Health and Fitness Industry, today ... as to MYiCLUBonline.  The latest upgrade includes advances ... inclusion of cardless check-in via Identity One fingerprint ... first time through interactive displays at the International ...
(Date:2/19/2015)... , Feb .19, 2015 Research and ... the addition of the "Military Electro-Optical / ... Sensor Technology, by Platform - Forecast to 2020" ... The military electro-optical/infrared systems market is expected to ... CAGR of 7.71%. This report segments ...
(Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... sub-Saharan Africa, according to the World Health Organization, and ... achieved limited success. But what if a vaccine against ... of Africa ?chancroid ?was relatively easy to develop and ... , That may be the case, according to researchers ...
... cells' own ability to correct themselves, will be outlined today ... European Society of Human Genetics in Amsterdam, The Netherlands. ... (commonly referred to as gene therapy) these new 'smart' approaches ... human biology. , Professor Brunhilde Wirth, from the Institute of ...
... technical advance in laboratory techniques may provide biology researchers ... the activity of targeted genes. RNA interference has recently ... function in normal biological processes and in disease. , ... on March 24, a research team from The Children's ...
Cached Biology News:Vaccine shown effective against chancroid 2Vaccine shown effective against chancroid 3'Smart' genetic therapy helps the body to heal itself 2'Smart' genetic therapy helps the body to heal itself 3'Smart' genetic therapy helps the body to heal itself 4Interfering RNA silences genes in 'slippery' immune cells 2Interfering RNA silences genes in 'slippery' immune cells 3
... structurally and functionally related BMPs, which are ... originally identified as protein regulators of cartilage ... in embryogenesis and morphogenesis of various tissues ... chemotaxis and apoptosis of various cell types, ...
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
RABBIT ANTI HUMAN CHYMOTRYPSIN...
MSE ANTI CAN. CD3:FITC/RAT ANTI CD4:RPE...
Biology Products: